8-K: Sagimet Biosciences Reports Positive Full Year 2024 Financial Results and Advances Clinical Programs

Sagimet Biosciences announces full year 2024 financial results, initiation of Phase 3 MASH program, FDA Breakthrough Therapy designation for denifanstat, and IND clearance for TVB-3567 for acne treatment.

Summary

• Sagimet Biosciences reported its full year 2024 financial results and provided corporate updates on March 12, 2025.
• The company initiated its Phase 3 denifanstat program in MASH in Q4 2024, with patient screening expected to start in 1H 2025.
• Denifanstat received Breakthrough Therapy designation from the FDA for MASH.
• The FDA cleared the Investigational New Drug (IND) application for FASN Inhibitor TVB-3567, which will be developed for the treatment of acne.
• Cash, cash equivalents, and marketable securities as of December 31, 2024, were $158.7 million, expected to fund operations for at least the next 12 months.
• The net loss for the year ended December 31, 2024, was $45.6 million, compared to $27.9 million for the year ended December 31, 2023.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with the initiation of Phase 3 trials, FDA Breakthrough Therapy designation, and a strong cash position. While there is a net loss, the overall tone is optimistic due to clinical advancements and potential for future growth.

Positives

• Initiation of Phase 3 program for denifanstat in MASH.
• FDA Breakthrough Therapy designation for denifanstat in MASH.
• Clearance of IND application for TVB-3567 for acne treatment.
• Completion of enrollment in Ascletis' Phase 3 clinical trial of denifanstat for acne in China.
• Strong cash position of $158.7 million, expected to fund operations for at least the next 12 months.
• Positive topline results from the Phase 2b FASCINATE-2 clinical trial, evaluating denifanstat in biopsy-confirmed MASH patients with stage F2 or F3 fibrosis compared to placebo at week 52.

Negatives

• Net loss for the year ended December 31, 2024, was $45.6 million, higher than the $27.9 million loss for the year ended December 31, 2023.
• The company is evaluating financing options to complete clinical development programs across indications.

Risks

• The company's clinical development plans and anticipated milestones are subject to risks and uncertainties.
• Unfavorable new clinical trial data may emerge in other clinical trials of denifanstat, including Phase 3 clinical trials.
• Clinical trial data are subject to differing interpretations and assessments, including by regulatory authorities.
• The company's relationship with Ascletis and the success of its development efforts for denifanstat are subject to risks.
• The company's estimates regarding its capital requirements may be inaccurate.
• The company's ability to maintain and successfully enforce adequate intellectual property protection is subject to risks.

Future Outlook

Sagimet anticipates several upcoming milestones, including the start of patient screening for the Phase 3 denifanstat program in MASH in the first half of 2025 and topline results from Ascletis' Phase 3 clinical trial of denifanstat for acne in China in the second quarter of 2025.

Management Comments

• 2024 was a highly productive year for Sagimet, and we are carrying that momentum into a strong start for 2025, said David Happel, Chief Executive Officer of Sagimet.
• We are pleased to have initiated our Phase 3 denifanstat program in MASH, with site activation and patient pre-screening underway and patient screening expected to begin soon.
• With the successful Phase 2b FASCINATE-2 results we reported in 2024, and Breakthrough Therapy designation granted by the FDA, we are confident in denifanstats potential to address the significant unmet need for patients living with MASH.
• Given the potential of FASN inhibition across multiple disease states, we look forward to progressing both denifanstat and TVB-3567 in the coming year.

Industry Context

Sagimet is focused on developing novel fatty acid synthase (FASN) inhibitors to target dysfunctional metabolic and fibrotic pathways in diseases like MASH and acne, addressing significant unmet needs in these areas. The company's lead drug candidate, denifanstat, is positioned as a differentiated therapy in the MASH landscape, which has seen increasing attention and recent regulatory approvals.

Comparison to Industry Standards

• The Phase 2b FASCINATE-2 trial results showed statistically significant and clinically meaningful improvements in disease activity, MASH resolution, and fibrosis, positioning denifanstat as a potential competitor to other MASH therapies in development.
• The Breakthrough Therapy designation from the FDA highlights the potential of denifanstat to address the unmet need for differentiated therapies in non-cirrhotic MASH with moderate to advanced liver fibrosis, similar to the accelerated development pathways pursued by other companies in the space.
• The initiation of the Phase 3 program for denifanstat in MASH aligns with the industry trend of advancing promising drug candidates into late-stage development to address the growing prevalence of MASH worldwide.
• Ascletis' Phase 3 clinical trial of denifanstat for acne in China reflects the increasing focus on developing therapies for dermatological conditions, similar to the efforts of companies like Seysara Tablets & Winlevi Cream.

Stakeholder Impact

• Shareholders may benefit from the potential for future growth and increased value due to the company's clinical advancements.
• Employees may experience increased job security and opportunities for advancement due to the company's progress.
• Patients may benefit from the development of new therapies for MASH and acne.
• The company's suppliers and partners may benefit from increased business opportunities due to the company's growth.

Next Steps

• Start patient screening for the Phase 3 denifanstat program in MASH in the first half of 2025.
• Await topline results from Ascletis' Phase 3 clinical trial of denifanstat for acne in China in the second quarter of 2025.
• Initiate a Phase 1 trial of TVB-3567 for acne in 2025.
• Continue evaluating financing options to complete clinical development programs across indications.

Key Dates